Millions of men over 50 face the same anxious sequence every year.
A blood test flags an elevated PSA level, then comes a biopsy, an invasive procedure that often turns up no dangerous cancer at all.
New research from the Medical University of Vienna suggests a scan taken before the biopsy could tell many of those men that they can safely skip it.
The team analyzed data from 194 men with elevated PSA who took part in the phase 3 RAPID trial.
Also read: Following these 8 habits may cut your risk of dying from cancer, large study suggests
PSMA-PET/CT, a scan that combines two imaging techniques, correctly detected 70 of the 77 men who turned out to have clinically significant prostate cancer, a hit rate of 91 percent.
Just as important, a clean scan meant no significant tumor in 91 percent of cases.
The findings appear in the inaugural issue of The Lancet Medical Imaging & Theranostics.
What is the PSMA-PET/CT?
The scan uses a small dose of a radioactive tracer that latches onto prostate-specific membrane antigen, a protein that sits in unusually high numbers on prostate cancer cells.
Also read: How food poisoning can affect your gut for years
A positron emission tomography camera then picks up where the tracer has stuck, while a simultaneous computed tomography image maps the exact anatomical spot.
In practice that means the scan can flag suspicious tissue with far greater specificity than a standard MRI or ultrasound alone.
Prostate biopsies remove tissue through the rectum or the skin behind the scrotum, and they carry a real risk of bleeding, infection and urinary trouble.
Skipping them safely, when the cancer is not there or not aggressive, is what makes the finding practical.
Also read: More than 100,000 people in Japan are over 100 – three traditions may help explain why
The follow-up numbers matter as much as the scan itself
Researchers tracked the same patients for a median of 35 months.
Of the 24 men who went on to develop aggressive disease over that period, 23 had already been picked up by the initial PSMA-PET/CT.
In other words, the scan not only spotted cancers that were already dangerous, it also flagged the ones that would become dangerous.
Marcus Hacker, head of the Division of Nuclear Medicine at the Medical University of Vienna, led the study together with Holger Einspieler and Sazan Rasul.
Also read: Levetiracetam paired with a blood thinner may nearly double clot risk
Hacker said the ability to rule cancer out is what makes the approach so useful in day-to-day diagnostics, because it spares men who do not have significant disease from an invasive procedure.
Not a green light for a full guideline change yet
This was a retrospective look at a single trial run at one center in Vienna, not a large multicenter rollout, and it will need to be repeated in bigger and more diverse populations before urology societies rewrite their pathways.
Standard guidance in the United States still recommends an MRI before biopsy in most men with elevated PSA, and any change in that sequence will move slowly through professional bodies.
For now, the takeaway for men with a rising PSA is not that they should demand a PSMA-PET/CT tomorrow.
Also read: 4 in 10 with fatty liver disease reversed scarring with one diet change and daily walks
It is a conversation to have with a urologist about whether imaging can narrow the decision before a biopsy is scheduled.
According to the American Cancer Society, prostate cancer is the most common cancer in American men aside from skin cancer, with an estimated 333,830 new cases and 36,320 deaths projected in the United States in 2026.
The Vienna team plans to expand the work in larger cohorts, which is the step guideline committees will be watching before they weigh a change.
This article is made and published by Ida-Marie Palm Varbæk, who may have used AI in the preparation.